Literature DB >> 11595513

Non-toxic ubiquitous over-expression of utrophin in the mdx mouse.

R Fisher1, J M Tinsley, S R Phelps, S E Squire, E R Townsend, J E Martin, K E Davies.   

Abstract

Duchenne muscular dystrophy (DMD) is an inherited, severe muscle wasting disease caused by the loss of the cytoskeletal protein, dystrophin. Patients usually die in their late teens or early twenties of cardiac or respiratory failure. We have previously demonstrated that the dystrophin related protein, utrophin is able to compensate for the loss of dystrophin in the mdx mouse, the mouse model of the disease. Expression of a utrophin transgene under the control of an HSA promoter results in localization of utrophin to the sarcolemma and prevents the muscle pathology. Here we show that the over-expression of full-length utrophin in a broad range of tissues is not detrimental in the mdx mouse. These findings have important implications for the feasibility of the up-regulation of utrophin in therapy for DMD since they suggest that tissue specific up-regulation may not be necessary.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595513     DOI: 10.1016/s0960-8966(01)00220-6

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  25 in total

1.  2015 William Allan Award.

Authors:  Kay E Davies
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

Review 2.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

3.  CT-GalNAc transferase overexpression in adult mice is associated with extrasynaptic utrophin in skeletal muscle fibres.

Authors:  Margaret Durko; Carol Allen; Josephine Nalbantoglu; George Karpati
Journal:  J Muscle Res Cell Motil       Date:  2010-08-13       Impact factor: 2.698

Review 4.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

5.  Ets-2 repressor factor silences extrasynaptic utrophin by N-box mediated repression in skeletal muscle.

Authors:  Kelly J Perkins; Utpal Basu; Murat T Budak; Caroline Ketterer; Santhosh M Baby; Olga Lozynska; John A Lunde; Bernard J Jasmin; Neal A Rubinstein; Tejvir S Khurana
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

Review 6.  Therapeutic approaches to muscular dystrophy.

Authors:  Aurélie Goyenvalle; Jane T Seto; Kay E Davies; Jeffrey Chamberlain
Journal:  Hum Mol Genet       Date:  2011-03-24       Impact factor: 6.150

Review 7.  Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.

Authors:  Christine Péladeau; Bernard J Jasmin
Journal:  RNA Biol       Date:  2020-11-19       Impact factor: 4.652

8.  Thermodynamic stability, unfolding kinetics, and aggregation of the N-terminal actin-binding domains of utrophin and dystrophin.

Authors:  Surinder M Singh; Justine F Molas; Narsimulu Kongari; Swati Bandi; Geoffrey S Armstrong; Steve J Winder; Krishna M G Mallela
Journal:  Proteins       Date:  2012-02-17

Review 9.  Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.

Authors:  Rebecca J Fairclough; Matthew J Wood; Kay E Davies
Journal:  Nat Rev Genet       Date:  2013-04-23       Impact factor: 53.242

10.  Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents.

Authors:  Steve D Wilton; Sue Fletcher
Journal:  Appl Clin Genet       Date:  2011-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.